Staff Reports
Governor Josh Shapiro showed up at B+labs in Philadelphia to sell a simple pitch: Pennsylvania is open for business in the life sciences, and he just locked $125 million into a new program called Innovate in PA 2.0 in the 2026–27 state budget. The governor leaned on big numbers — Ely Lilly and Johnson & Johnson are pouring billions into the state — and on familiar statistics about patents and jobs to argue the Commonwealth is poised for more growth. Fine. But applause at a ribbon‑cutting isn’t the same as a plan that will actually work for taxpayers and startups alike.
What Innovate in PA 2.0 Actually Says It Will Do
The budget line promises to use Insurance Premium Tax Credits to backstop a $125 million slate of investments meant to seed startups, build a statewide clinical‑trial network, and commercialize university inventions. The administration says the goal is to turn Pennsylvania’s research base into companies and jobs — and notes the life sciences sector already employs over 100,000 people here. Those are useful aims: seed capital and clinical trial pipelines can help firms go from lab bench to marketplace.
Good News — But Where’s the Fine Print?
Here’s where the conservative skeptic in me replaces the ribbon‑cutting smile with a clipboard. The announcement gives goals, not guardrails. Who will run Innovate in PA 2.0? Will money be distributed by competitive grants, matching funds, or backdoor deals with politically connected fund managers? How will success be measured — jobs created, private dollars leveraged, patents commercialized? And will taxpayers be protected if a chunk of this public support lines the pockets of insiders instead of building durable, statewide capacity?
Private Investment Is Great — The State Shouldn’t Try to Play Venture Capital
It’s worth celebrating Eli Lilly and Johnson & Johnson choosing Pennsylvania for big manufacturing projects. Those are private bets on our workforce and infrastructure. The state’s best role is not to become a venture capitalist in chief but to remove roadblocks: train workers, upgrade labs and grid, cut red tape, and ensure transparency so private capital is attracted for the right reasons. If Innovate in PA 2.0 can be a lever to help local suppliers and clinical partners benefit from those big deals, fine — but show the plan and the metrics.
Bottom Line — Support Growth, Demand Accountability
Governor Shapiro’s life‑sciences pitch fits a smart economic theme: grow high‑paying jobs and commercialize great research. Conservatives should applaud the focus on jobs and innovation — and then insist on daylight. Before cheering $125 million, demand details about administration, oversight, sunset clauses, and measurable returns. Celebrate the wins, but don’t let the applause drown out common‑sense questions about who exactly benefits and how taxpayers are protected. After all, momentum’s great — but a tether to accountability is what keeps the show from flying off the rails.
